Teva sues Mylan in US for Copaxone infringement
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has filed suit in the US District Court for the Southern District of New York against Mylan Pharmaceuticals, alleging that its ANDA referencing the multiple sclerosis agent Copaxone (glatiramer acetate injection) infringes certain patents. Teva has also sued the Indian company Natco Pharma over similar claims.